{"title":"关于“atezolizumab联合贝伐单抗治疗晚期肝细胞癌患者额外放疗的可行性”的信函。","authors":"Sun Hyun Bae, Hee Chul Park","doi":"10.17998/jlc.2023.08.18","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":" ","pages":"402-404"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/40/jlc-2023-08-18.PMC10565551.pdf","citationCount":"0","resultStr":"{\"title\":\"Letter regarding \\\"Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab\\\".\",\"authors\":\"Sun Hyun Bae, Hee Chul Park\",\"doi\":\"10.17998/jlc.2023.08.18\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":16226,\"journal\":{\"name\":\"Journal of Liver Cancer\",\"volume\":\" \",\"pages\":\"402-404\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/40/jlc-2023-08-18.PMC10565551.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Liver Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17998/jlc.2023.08.18\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Liver Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17998/jlc.2023.08.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Letter regarding "Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab".